ECSP099225A - Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso - Google Patents

Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso

Info

Publication number
ECSP099225A
ECSP099225A EC2009009225A ECSP099225A ECSP099225A EC SP099225 A ECSP099225 A EC SP099225A EC 2009009225 A EC2009009225 A EC 2009009225A EC SP099225 A ECSP099225 A EC SP099225A EC SP099225 A ECSP099225 A EC SP099225A
Authority
EC
Ecuador
Prior art keywords
compounds
compositions containing
use procedures
glucagon
receiver antagonist
Prior art date
Application number
EC2009009225A
Other languages
English (en)
Inventor
James R Tata
Emma R Parmee
John E Stelmach
Keith G Rosauer
Ronald M Kim
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38982644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP099225A publication Critical patent/ECSP099225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describen compuestos antagonistas del receptor de glucagón. Los compuestos son útiles para tratar diabetes tipo 2 y estados patológicos relacionados. También se incluyen composiciones farmacéuticas y procedimientos de tratamiento
EC2009009225A 2006-10-03 2009-04-03 Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso ECSP099225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84896706P 2006-10-03 2006-10-03

Publications (1)

Publication Number Publication Date
ECSP099225A true ECSP099225A (es) 2009-07-31

Family

ID=38982644

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009225A ECSP099225A (es) 2006-10-03 2009-04-03 Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso

Country Status (30)

Country Link
US (3) US20100004158A1 (es)
EP (1) EP2079688B1 (es)
JP (1) JP2010505828A (es)
KR (1) KR20090076907A (es)
CN (1) CN101535252A (es)
AR (1) AR063022A1 (es)
AU (1) AU2007305430B2 (es)
BR (1) BRPI0717305A2 (es)
CA (1) CA2664004C (es)
CL (1) CL2007002841A1 (es)
CO (1) CO6190512A2 (es)
CR (1) CR10694A (es)
DK (1) DK2079688T3 (es)
EA (1) EA017800B1 (es)
EC (1) ECSP099225A (es)
ES (1) ES2390296T3 (es)
GE (1) GEP20125506B (es)
IL (1) IL197788A0 (es)
MA (1) MA31963B1 (es)
MX (1) MX2009003611A (es)
NO (1) NO342172B1 (es)
PE (1) PE20080676A1 (es)
PL (1) PL2079688T3 (es)
PT (1) PT2079688E (es)
SI (1) SI2079688T1 (es)
TN (1) TN2009000111A1 (es)
TW (1) TW200821284A (es)
UA (1) UA96308C2 (es)
WO (1) WO2008042223A1 (es)
ZA (1) ZA200901694B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418212A (pt) * 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
AU2007229850A1 (en) * 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009537525A (ja) * 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、このような化合物を含む組成物及び使用方法
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP5322951B2 (ja) 2007-02-09 2013-10-23 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体の新規アンタゴニスト
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2717138A1 (en) 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
KR101599089B1 (ko) 2008-08-13 2016-03-02 메타베이시스 테라퓨틱스, 인크. 글루카곤 길항제
US8436015B2 (en) * 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2350020B1 (en) * 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
US8445538B2 (en) * 2008-12-19 2013-05-21 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
WO2010080971A1 (en) * 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010093535A1 (en) * 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) * 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2015066252A1 (en) * 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
CN107304180B (zh) * 2016-04-22 2022-04-29 浙江海正药业股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN109071420B (zh) * 2016-06-14 2021-06-18 上海昂睿医药技术有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
CN107759522B (zh) * 2016-08-15 2023-04-14 浙江海正药业股份有限公司 羧酸类衍生物、其制备方法及其在医药上的用途
SG10201913074WA (en) 2016-08-30 2020-03-30 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU728760B2 (en) 1996-11-20 2001-01-18 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ATE389636T1 (de) 1997-12-19 2008-04-15 Amgen Inc Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung
JP2002544254A (ja) 1999-05-17 2002-12-24 ノボ ノルディスク アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
HUP0301501A2 (hu) 2000-06-23 2003-08-28 Novo Nordisk A/S Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002083628A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
CN1283621C (zh) * 2001-09-18 2006-11-08 霍夫曼-拉罗奇有限公司 烷基脲的类维生素a激动剂ⅰ
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
CN100543022C (zh) 2002-02-01 2009-09-23 大日本住友制药株式会社 2-呋喃甲酸酰肼化合物及含该化合物的药物组合物
WO2004002480A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
WO2004020409A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US8318760B2 (en) * 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
PE20080676A1 (es) 2008-06-12
US20080085926A1 (en) 2008-04-10
US7968589B2 (en) 2011-06-28
BRPI0717305A2 (pt) 2014-03-25
AU2007305430A1 (en) 2008-04-10
DK2079688T3 (da) 2012-11-05
US20100004158A1 (en) 2010-01-07
JP2010505828A (ja) 2010-02-25
TW200821284A (en) 2008-05-16
EA200970342A1 (ru) 2009-10-30
AR063022A1 (es) 2008-12-23
PT2079688E (pt) 2012-11-22
WO2008042223A1 (en) 2008-04-10
CO6190512A2 (es) 2010-08-19
ES2390296T3 (es) 2012-11-08
TN2009000111A1 (en) 2010-08-19
CA2664004A1 (en) 2008-04-10
SI2079688T1 (sl) 2012-12-31
EA017800B1 (ru) 2013-03-29
IL197788A0 (en) 2009-12-24
KR20090076907A (ko) 2009-07-13
GEP20125506B (en) 2012-04-25
MX2009003611A (es) 2009-04-22
UA96308C2 (ru) 2011-10-25
EP2079688B1 (en) 2012-07-25
US7687534B2 (en) 2010-03-30
ZA200901694B (en) 2010-01-27
MA31963B1 (fr) 2011-01-03
US20100144824A1 (en) 2010-06-10
NO342172B1 (no) 2018-04-09
CA2664004C (en) 2013-07-23
NO20091734L (no) 2009-06-04
AU2007305430B2 (en) 2011-07-21
EP2079688A1 (en) 2009-07-22
CN101535252A (zh) 2009-09-16
PL2079688T3 (pl) 2013-01-31
CL2007002841A1 (es) 2008-02-08
CR10694A (es) 2009-05-25

Similar Documents

Publication Publication Date Title
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
GT200600453A (es) Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
ECSP088222A (es) Agonistas de receptores adrenérgicos alfa2c funcionalmente selectivos
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
CL2013000685A1 (es) Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
TW200800967A (en) Benzimidazole thiophene compounds
DE602006012694D1 (de) Benzimidazolthiophenverbindungen als plk-modulatoren
AR058127A1 (es) Derivados de piperidina antagonistas de cgrp, procedimientos para su preparacion asi como su uso como medicamentos
CL2008002708A1 (es) Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo,
CR11500A (es) Derivados ciclopropilamina
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
UY30801A1 (es) Compuestos calciliticos
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.